{
  "@type": "dcat:Dataset",
  "accessLevel": "public",
  "accrualPeriodicity": "R/P1Y",
  "bureauCode": [
    "009:10"
  ],
  "contactPoint": {
    "@type": "vcard:Contact",
    "fn": "Division of Drug Information",
    "hasEmail": "mailto:druginfo@fda.hhs.gov"
  },
  "description": "Novolog (insulin aspart) is a fast-acting insulin analog used to control blood sugar in people with diabetes. It's injected subcutaneously or intravenously, available in pens, syringes, and vials at 100 units/mL strength. Manufactured by Novo Nordisk, it's prescribed for managing type 1 or 2 diabetes. This information was generated using AI and is provided for informational and research purposes only.",
  "distribution": [
    {
      "@type": "dcat:Distribution",
      "description": "\n        Access the FDA dataset for Insulin aspart — ANDA 020986 submitted by Mylan Institutional LLC\n    ",
      "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020986",
      "mediaType": "text/html",
      "title": "Insulin aspart"
    }
  ],
  "identifier": "ANDA020986",
  "issued": "2016-09-16",
  "keyword": [
    "drug-manufacturers",
    "drug-safety",
    "fda",
    "health-care",
    "public-health"
  ],
  "landingPage": "https://www.fda.gov/drugs",
  "license": "https://open.fda.gov/license",
  "modified": "2025-03-17",
  "programCode": [
    "009:002"
  ],
  "publisher": {
    "@type": "org:Organization",
    "name": "U.S. Food and Drug Administration"
  },
  "theme": [
    "FDA"
  ],
  "title": "Insulin aspart"
}